Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

Borislav Kondov; Zvonko Milenkovikj; Goran Kondov; Gordana Petrushevska; Neli Basheska; Magdalena Bogdanovska-Todorovska; Natasha Tolevska; Ljube Ivkovski

doi:10.3889/oamjms.2018.231

Authors

Borislav Kondov University Clinic for Thoracic and Vascular Surgery, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Zvonko Milenkovikj University Clinic for Infectious Disease and Febrile Conditions, Ss Cyril and Methodius University of Skopje, Skopje
Goran Kondov University Clinic for Thoracic and Vascular Surgery, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Gordana Petrushevska Institute of Pathology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Neli Basheska Laboratory for Cytology and Pathology, University Clinic of Oncology and Radiotherapy, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Magdalena Bogdanovska-Todorovska Institute of Pathology, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Natasha Tolevska University Clinic for Thoracic and Vascular Surgery, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje
Ljube Ivkovski PZU Histolab, Skopje

DOI:

https://doi.org/10.3889/oamjms.2018.231

Keywords:

subtypes of breast cancer, Luminal A, Luminal B HER-2 negative, Luminal B HER-2 positive, HER-2 enriched, triple negative

Abstract

INTRODUCTION: The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, with each subtype manifesting certain prognosis and aggression.

AIM: Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and Vascular Surgery.

MATERIAL AND METHODS: We used the international classification on molecular subtypes of breast cancer which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 â‰¥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed during 2014.

RESULTS: In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) patients.

CONCLUSION: Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer is necessary for the routine histopathological assay.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Justo N, Wilking N, JÃ¶nsson B, Luciani S, Cazap E. A Review of Breast Cancer Care and Outcomes in Latin America. Oncologist. 2013; 18(3): 248â€“256. https://doi.org/10.1634/theoncologist.2012-0373 PMid:23442305 PMCid:PMC3607519

Bhikoo R, Srinivasa S, Tzu-Chieh Yu, Moss D, Hill G A. Systematic Review of Breast Cancer Biology in Developing Countries (Part 1): Africa, the Middle East, Eastern Europe, Mexico, the Caribbean and South America. Cancers (Basel). 2011; 3(2): 2358â€“2381. https://doi.org/10.3390/cancers3022358 PMid:24212814 PMCid:PMC3757422

Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(Spec No.):43-6.

Global cancer observatory. www. gco.iarc.fr

Prat A, Pineda E, Adamo B, GalvÃ¡n P, FernÃ¡ndez A, Gaba L, DÃez M, Viladot M, Arance A, Mu-oz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24(Suppl 2):S26-35. https://doi.org/10.1016/j.breast.2015.07.008 PMid:26253814

Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X, Giuliano AE. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg. 2014; 149(2):125-9. https://doi.org/10.1001/jamasurg.2013.3181 PMid:24306257

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, ThÃ¼rlimann B, Senn HJ. Panel members- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 2013; 24: 2206â€“2223. https://doi.org/10.1093/annonc/mdt303 PMid:23917950 PMCid:PMC3755334

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. https://doi.org/10.1245/s10434-010-0985-4 PMid:20180029

Uehiro N, Horii R, Iwase T, Tanabe M, Sakai T, Morizono H, Kimura K, Iijima K, Miyagi Y, Nishimura S, Makita M, Ito Y, Akiyama F. Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer. Breast Cancer. 2014; 21(6):748-53. https://doi.org/10.1007/s12282-013-0453-7 PMid:23435963

Benis S, Abbass F, Akasbi Y, Znati K, Joutel KA, Mesbahi O, Amarati A. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco. BMC Reasrch notes. 2012; 5:436. https://doi.org/10.1186/1756-0500-5-436 PMid:22889054 PMCid:PMC3532150

PÃ©rez-RodrÃguez G. Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cir Cir. 2015; 83(3):193-8. https://doi.org/10.1016/j.circen.2015.09.017

Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, Inic I, Pupic G, Jancic S. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights Oncol. 2014; 8:107-11.2014.

Williams C, Chin-Yo Lin. Oestrogen receptors in breast cancer: basic mechanisms and clinical implicastions. Ecancermedicalscience, 2013; 7: 370. PMid:24222786 PMCid:PMC3816846

Gutierrez C, Schiff R. HER 2: Biolgy, Detection, and Clinical Implications; Arch Pathol Lab Med. 2011; 135(1): 55â€“62. PMid:21204711 PMCid:PMC3242418

van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004; 57(7): 675â€“681. https://doi.org/10.1136/jcp.2003.010777 PMid:15220356 PMCid:PMC1770351

Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, Nisar M, Siddiqui M, Edhi MM, Faridi N, Khan A. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018; 16(1):1. https://doi.org/10.1186/s12957-017-1299-9 PMid:29291744 PMCid:PMC5749004

Carey LA, Dees EC, Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13:2329â€“2334. https://doi.org/10.1158/1078-0432.CCR-06-1109 PMid:17438091

Vallejos CS, GÃ³mez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup SP, LeÃ³n M, de la Cruz MA, Vigil CE. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010; 10(4):294-300. https://doi.org/10.3816/CBC.2010.n.038 PMid:20705562

Eroles P, Bosch A, PÃ©rez-Fidalgo J A, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews. 2012; 38(6):698-707. https://doi.org/10.1016/j.ctrv.2011.11.005 PMid:22178455

Liedtke C, Kiesel L. Breast cancer molecular subtypes- Modern therapeutic concepts for targeted therapy of a heterogeneous entity. Maturitas. 2012; 73(4):288-294. https://doi.org/10.1016/j.maturitas.2012.08.006 PMid:23020990

Del Casar JM, Martin A, Garcia C, Corte MD, Alvarez A,Junquera S, Gonzalez LO, Bongera M, Garcia-Muniz JL, Allende MT, Vizoso F. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: Relationship with clinicopathological characteristics, biological features and prognosis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2008; 141(2):147-152. https://doi.org/10.1016/j.ejogrb.2008.07.021 PMid:18768247

Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. Breast. 2013; 22:S106-S109. https://doi.org/10.1016/j.breast.2013.07.020 PMid:24074769

GarcÃa FernÃ¡ndez A, GimÃ©nez N, Fraile M, GonzÃ¡lez S, Chabrera C, Torras T, GonzÃ¡lez C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast. 2012; 21(3):366-373. https://doi.org/10.1016/j.breast.2012.03.004 PMid:22487206

Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F, Paci E. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013; 139(4):617â€“623. https://doi.org/10.1007/s00432-012-1365-1 PMid:23269487

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA. Protein expression profile and prevalence pattern of the molecular classes of breast cancerâ€”a Saudi population based study. BMC Cancer. 2010; 10(1):223. https://doi.org/10.1186/1471-2407-10-223 PMid:20492711 PMCid:PMC2880995

Zhu X, Ying J, Wang F, Wang J, Yang H. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China. Breast Cancer Res Treat. 2014; 147(3):551â€“555. https://doi.org/10.1007/s10549-014-3136-y PMid:25234844

Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagara Y, Kamada Y, Tamaki N. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. Breast Cancer. 2011; 18(4):292â€“298. https://doi.org/10.1007/s12282-010-0209-6 PMid:20571962

Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, DuQuette RA, Resau J, Carpten J. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011; 11(1):44. https://doi.org/10.1186/1472-6874-11-44 PMid:21961708 PMCid:PMC3204283

Kan C, Patel RB, Biswas T. Distribution of Newly Diagnosed Breast Cancers by Subtype and Race Using the SEER Database. International Journal of Radiation Oncology, Biology, Physics. 2015; 93(3):E24-E24. https://doi.org/10.1016/j.ijrobp.2015.07.605

Marrazzo A, Boscaino G, Marrazzo E, Taormina P, Toesca A. Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study. International Journal of Surgery. 2015; 21:156-161. https://doi.org/10.1016/j.ijsu.2015.07.702 PMid:26253849

Crabb SJ, Cheang MCU, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK. Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer. Clinical Breast Cancer. 2008; 8(3):249-256. https://doi.org/10.3816/CBC.2008.n.028 PMid:18650155

Van Calster B, Vanden Bempt I, Drijkoningen M, Pochet N, Cheng J, Van Huffel S, Hendrickx W, Decock J, Huang HJ, Leunen K, Amant F, Berteloot P, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Timmerman D, Van Gorp T, Smeets A, Van den Bogaert W, Vergote I, Christiaens MR, Neven P. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat. 2009; 113(1):181-7. https://doi.org/10.1007/s10549-008-9914-7 PMid:18264760

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9):1217-26. https://doi.org/10.1016/j.humpath.2006.04.015 PMid:16938528

Lee JH, Suh YJ, Shim BY, Kim SH. The incidence and predictor of lymph node metastasis for patients with T1mi breast cancer that underwent axillary dissection and breast irradiation: an institutional analysis. Jpn J Clin Oncol. 2011; 41(10):1162-7. https://doi.org/10.1093/jjco/hyr128 PMid:21903706

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012; 133(3);831-41. https://doi.org/10.1007/s10549-011-1891-6 PMid:22147079